AL-8810

• Description :

  AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor) . AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG) [1][2][3][4][5].

• CAS Number :

  [246246-19-5]

• UNSPSC :

  12352005

• Target :

  ERK; p38 MAPK; Prostaglandin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Endocrinology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/al-8810.html

• Purity :

  99.00

• Solubility :

  10 mM in DMSO|DMSO : ≥ 10mg/mL

• Smiles :

  O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](C2CC3=C(C=CC=C3)C2)O)[C@@H](F)C[C@@H]1O

• Molecular Formula :

  C24H31FO4

• Molecular Weight :

  402.50

• References & Citations :

  [1]Griffin BW, et al. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999 Sep;290 (3) :1278-84.|[2]Kim YT, et al. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol Dis. 2012 Oct;48 (1) :58-65. doi: 10.1016/j.nbd.2012.06.003. Epub 2012 Jun 16.|[3]Goupil E, et al. Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol Endocrinol. 2012 Jul;26 (7) :1189-202.|[4]Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176 (8) :1059-1078.|[5]Glushakov AV, et al. Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation. 2013 Oct 30;10:132.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported